Almirall, proud sponsor at the next EADV Congress 2026, reinforcing our commitment to Medical Dermatology. This year the congress will be hosted in the city of Vienna (Austria) from 30th September to 3rd October 2026.
Almirall, proud sponsor at the next EADV Congress 2026, reinforcing our commitment to Medical Dermatology.
This year the congress will be hosted in the city of Vienna (Austria) from 30th September to 3rd October 2026.
Our scientific sessions
A range of Scientific Sessions presenting the latest evidence-based data at the EADV Congress 2026. Almirall sessions will run on Thursday 1st and Friday 2nd October. Don’t miss our AD HUB and two inspiring Symposia with world leading panellists, and keep on building the future of medical dermatology with Almirall.
AD HUB
Thursday,
1 October
From 9:15
to 10:00 CEST
HUB 2.07
HUB 2,
-2.41 /
-2.42, Level -2
Looking into the face of AD: tackling clinical cases in moderate-to-severe atopic dermatitis with face and neck involvement including lebrikizumab▼
9:15
Welcome & introduction
Prof. Christian Vestergaard
9:20
The wish for urgent relief, and stable response in the visible areas and beyond*
Prof. Christian Vestergaard and Ass. Prof. Marie Jachiet
9:35
Maintaining long-term sustained response in AD including challenging areas*
Prof. Christian Vestergaard and Ass. Prof. Marie Jachiet
9:55
Q&A and closing
Prof. Christian Vestergaard and Ass. Prof. Marie Jachiet
* Including discussions of cases on face & neck AD.
- See the complete agenda
- Close the complete agenda
Why attend
Join us for an interactive discussion focused on moderate-to-severe atopic dermatitis with face and neck involvement, where clinical complexity often meets high patient burden. Through real-life cases and expert exchange, explore practical considerations in recognition, assessment, and management, and gain valuable insights into how treatment strategies with advanced systemic therapies including lebrikizumab may be applied in patients with challenging visible disease.
AD, atopic dermatitis
▼ EBGLYSS® is approved by EMA and authorised for commercialisation in a number of key markets including Germany, Spain and the United Kingdom. Access EBGLYSS® full SmPC clicking here. Click here for lebrikizumab SmPC. UK and Irish healthcare professionals, click here for UK/IE prescribing information and adverse event reporting instructions. These sessions are organized and funded by Almirall S.A. Almirall product will be discussed. Almirall event, booth and website are intended for healthcare professionals registered at the Congress.
Symposium on psoriasis
Thursday,
1 October
From 17:45
to 18:45 CEST
SAT 11.04
Hall N, Level 1
Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control
17:45
Redefining treatment success through patient-centered care
Prof. Ulrich Mrowietz
17:55
How to integrate patient perspectives into treatment decisions:
insights from
the POSITIVE study
Prof. Matthias Augustin
18:10
Where it matters most: managing psoriasis in high-impact areas and ageing populations
Prof. Anna López-Ferrer
18:25
Achieving sustained disease control in complex patients through tailored treatment with tildrakizumab
Prof. Paolo Gisondi
18:40
Q&A and closing
Prof. Ulrich Mrowietz
Prof. Matthias Augustin
Prof. Anna López-Ferrer
Prof. Paolo Gisondi
- See the complete agenda
- Close the complete agenda
Why attend
This symposium highlights a value-based, patient-centred approach to psoriasis management, moving beyond traditional metrics to focus on sustained disease control, quality of life, and patient-reported outcomes. Attendees will gain practical strategies to integrate functional impairment and psychological burden into routine clinical decision-making. It provides real-world, evidence-based guidance on achieving durable responses, treatment persistence, and long-term safety in chronic disease management. Emphasis is placed on tailoring treatment according to individual patient characteristics, enabling a personalized approach.
PASI, Psoriasis Area Severity Index.
These sessions are organized and funded by Almirall S.A. Almirall product will be discussed. Almirall event, booth and website are intended for healthcare professionals registered at the Congress.
Symposium on atopic dermatitis
Friday,
2 October
From 13:00
to 14:00 CEST
SAT 5.06
Hall F2, Level 0
The many faces of AD – spotlight on visible burden, deep response, and simplicity in everyday care with lebrikizumab▼
13:00
Welcome & introduction
Dr. Christine Bangert
13:05
Facing the visible burden: addressing the pathophysiology and introducing new clinical evidence for face & neck atopic dermatitis
Dr. Christine Bangert
13:25
Rethinking AD control: stability and deep response across body regions in AD
Prof. Diamant Thaçi
13:45
Simplifying the journey: practical considerations in modern AD management
Dr. Constanza Riquelme
13:55
Q&A and closing
Dr. Christine Bangert
Prof. Diamant Thaçi
Dr. Constanza Riquelme
- See the complete agenda
- Close the complete agenda
Why attend
Join us to explore the many faces of atopic dermatitis and the challenges that matter in everyday practice – from the visible burden of face and neck involvement to the importance of achieving long-term sustained response across body regions. Discover emerging clinical evidence, gain insights into the new innovative evidence being generated on the difficult-to-treat regions of face and neck, and hear expert perspectives on practical approaches to simplifying modern AD management with lebrikizumab.
AD, atopic dermatitis
▼ EBGLYSS® is approved by EMA and authorised for commercialisation in a number of key markets including Germany, Spain and the United Kingdom. Access EBGLYSS® full SmPC clicking here. Click here for lebrikizumab SmPC. UK and Irish healthcare professionals, click here for UK/IE prescribing information and adverse event reporting instructions. These sessions are organized and funded by Almirall S.A. Almirall product will be discussed. Almirall event, booth and website are intended for healthcare professionals registered at the Congress.
Almirall’s faculty at EADV Congress 2026
Prof. Matthias Augustin
Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control
Thursday, 1 October 2026
From 17:45 to 18:45 CEST
Dr. Christine Bangert
The many faces of AD – spotlight on visible burden, deep response, and simplicity in everyday care with lebrikizumab▼
Friday, 2 October 2026
From 13:00 to 14:00 CEST
Prof. Paolo Gisondi
Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control
Thursday, 1 October 2026
From 17:45 to 18:45 CEST
Assoc. Prof. Marie Jachiet
Looking into the face of AD: tackling clinical cases in moderate-to-severe atopic dermatitis with face and neck involvement including lebrikizumab
Thursday, 1 October 2026
From 9:15 to 10:00 CEST
Prof. Anna López-Ferrer
Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control
Thursday, 1 October 2026
From 17:45 to 18:45 CEST
Prof. Ulrich Mrowietz
Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control
Thursday, 1 October 2026
From 17:45 to 18:45 CEST
Dr. Constanza Riquelme
The many faces of AD – spotlight on visible burden, deep response, and simplicity in everyday care with lebrikizumab
Friday, 2 October 2026
From 13:00 to 14:00 CEST
Prof. Diamant Thaçi
The many faces of AD – spotlight on visible burden, deep response, and simplicity in everyday care with lebrikizumab
Friday, 2 October 2026
From 13:00 to 14:00 CEST
Prof. Christian Vestergaard
Looking into the face of AD: tackling clinical cases in moderate-to-severe atopic dermatitis with face and neck involvement including lebrikizumab
Thursday, 1 October 2026
From 9:15 to 10:00 CEST
Any questions?
Contact us if you need more information related to Almirall portfolio.